Alexandria Real Estate Equities, Inc.
AREAlexandria Real Estate Equities, Inc. (ARE) is a real estate investment trust (REIT) specializing in the ownership, operation, and development of innovative office, laboratory, and technology campuses primarily located in major life science hubs across the United States. The company focuses on properties that support the growth of the life sciences industry, including biotech, pharmaceutical, and research firms. Founded in 1994, Alexandria REIT is known for its high-quality, sustainable properties and strategic emphasis on tenants engaged in scientific and health-related research.
Dividend History
Investors can expect a dividend payout of $0.72 per share, scheduled to be distributed in 38 days on January 15, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 15, 2026 | $0.72 | 2025-12-31 | 2025-12-31 |
| October 15, 2025 | $1.32 | 2025-09-30 | 2025-09-30 |
| July 15, 2025 | $1.32 | 2025-06-30 | 2025-06-30 |
| April 15, 2025 | $1.32 | 2025-03-31 | 2025-03-31 |
| January 15, 2025 | $1.32 | 2024-12-31 | 2024-12-31 |
Dividends Summary
- Alexandria Real Estate Equities, Inc. has issued 89 dividend payments over the past 22 years
- The most recent dividend was paid 54 days ago, on October 15, 2025
- The highest dividend payed out to investors during this period was $1.32 per share
- The average dividend paid during this period was $0.82 per share.
Company News
Alexandria Real Estate Equities is facing a securities fraud lawsuit after announcing lower occupancy rates, slower leasing activity, and a significant $323.9 million real estate impairment charge, causing its stock to drop over 19%.
Alexandria Real Estate Equities announced a 45% reduction in its quarterly dividend to $0.72 per share, payable on January 15, 2026. The dividend reduction aims to strengthen the company's balance sheet and preserve capital.
The article examines the three highest dividend-paying stocks in the S&P 500, highlighting their current challenges and potential risks for investors during an economic downturn.
Alexandria Real Estate has experienced significant stock price decline due to post-pandemic biotech funding normalization, with sales growth decelerating and potential funding challenges. Despite current uncertainties, the company remains financially stable with a well-covered dividend.
Robust demand for Alexandria's (ARE) high-quality life science and lab office properties in key markets, healthy operating performance and expansion efforts bode well for long-term growth.
